Price-sensitive press releases
2024-06-28
Moberg Pharma AB (publ) (the “Company”) today announces that the number of ordinary shares in the Company has increased to a total of 47,016,521 due to the exercise of warrants of series 2023:1 (“TO 2”) and due to the issue of C-shares which subsequently were converted into ordinary shares and repurchased by the Company to secure the Company's commitments under incentive programmes.
2024-06-24
(“Moberg Pharma” or the “Company”) announces that 17,776,856 warrants of series 2023:1 (“TO 2”) were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11[th], 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK 16 million to the top guarantors to fulfil the top guarantee commitments (the “Share Issue”). Through the exercise of TO 2 and the Share Issue, Moberg Pharma thus receives approximately SEK 336 million before issue costs.
2024-06-17
Today, June 17[th], 2024, is the last day for trading in Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2023:1 (“TO 2”). The exercise period runs until June 19[th], 2024.
2024-06-11
Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1 (“TO 2”), from a few external professional investors and the Company's largest shareholder, Östersjöstiftelsen (The Baltic Sea Foundation).
2024-06-05
Today, the exercise period for Moberg Pharma AB (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2023:1 begins. The exercise period runs during the period from and including June 5[th], 2024, up to and including June 19[th], 2024. The last day for trading in warrants of series 2023:1 on Nasdaq Stockholm is June 17[th], 2024.
2024-05-31
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today announces that the subscription price for ordinary shares upon exercise of warrants of series 2023:1 is SEK 18.00 per ordinary share. The exercise period begins on June 5[th], 2024, and runs until June 19[th], 2024. The last day for trading in warrants of series 2023:1 on Nasdaq Stockholm is June 17[th], 2024.
2024-05-14
STOCKHOLM, May 14[th], 2024. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2024-04-12
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 14 May 2024 at 14:00 at Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2024-04-12
Moberg Pharma´s Annual report for 2023 has been published and is available on www.mobergpharma.se
2024-02-19
STOCKHOLM, February 19[th], 2024. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2024.
2024-02-07
STOCKHOLM, February 7[th], 2024, Moberg Pharma ABs (OMX: MOB) marker partner in Sweden – Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of MOB-015 under the Terclara[®] brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.